Off-label, not off-limits: the FDA needs to create a safe harbor for off-label drug use.
作者信息
Howard Paul, Copland James
出版信息
Mo Med. 2013 Mar-Apr;110(2):106-9.
Abstract
摘要
相似文献
1
Off-label, not off-limits: the FDA needs to create a safe harbor for off-label drug use.
Mo Med. 2013 Mar-Apr;110(2):106-9.
2
Court rules that FDA cannot restrict off-label marketing.
BMJ. 2015 Aug 11;351:h4367. doi: 10.1136/bmj.h4367.
3
Regulating Off-Label Promotion - A Critical Test.
N Engl J Med. 2016 Dec 15;375(24):2313-2315. doi: 10.1056/NEJMp1611755. Epub 2016 Nov 2.
4
Off-label marketing and the First Amendment.
N Engl J Med. 2013 Jan 10;368(2):103-5. doi: 10.1056/NEJMp1214926. Epub 2012 Dec 12.
5
Free speech rights outweigh restrictions on promoting drugs off label, court rules.
BMJ. 2012 Dec 6;345:e8324. doi: 10.1136/bmj.e8324.
6
The limits of free speech.
Nature. 2012 Dec 20;492(7429):311. doi: 10.1038/492311a.
7
Prospects for Enforcing Prohibitions on Off-Label Drug Promotion after United States v. Caronia: An Analysis of Litigated Cases.
J Health Polit Policy Law. 2021 Jun 1;46(3):487-504. doi: 10.1215/03616878-8893571.
8
Commercial speech and off-label drug uses: what role for wide acceptance, general recognition and research incentives?
Am J Law Med. 2011;37(2-3):258-77. doi: 10.1177/009885881103700203.
9
Lawsuit challenges FDA's authority to prevent off-label marketing.
BMJ. 2015 May 12;350:h2587. doi: 10.1136/bmj.h2587.
10
Off-label marketing: free speech or illegal promotion?
BMJ. 2013 Jan 22;346:f320. doi: 10.1136/bmj.f320.
引用本文的文献
1
Long-term inhaled granulocyte macrophage-colony-stimulating factor in autoimmune pulmonary alveolar proteinosis: effectiveness, safety, and lowest effective dose.
Clin Drug Investig. 2014 Aug;34(8):553-64. doi: 10.1007/s40261-014-0208-z.
Zotero 插件